For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

Mitochondrial biology research

NAD+ Dosage, Protocol & Research Guide

By Sam, MBA

  • MW 663.4 g/mol
  • CAS 53-84-9
Dosage, protocol, reconstitution and storage reference for NAD+, with a reconstitution calculator, vial sizes and cited research.

Dose overview

Every range below is taken from the cited source and carries its evidence grade.

Human data and community reports

Human data and community reports
SourcePopulationDoseFrequencyRouteDurationEvidence
Human clinical trial[2]human180 adults with heart failure due to ischemic cardiomyopathy (LVEF 45% or lower, NYHA class II-III), alongside guideline-directed medical therapy10 mg[2]intravenous, trial dose 10 mg per day for 7 days versus placebodaily for 7 daysintravenous— Human clinical trialStudy details from the source: Single-center randomized placebo-controlled trial in ischemic cardiomyopathy heart failure (Am J Cardiovasc Drugs 2026, doi 10.1007/s40256-025-00764-7; 180 adults): intravenous NAD+ 10 mg/day or placebo for 7 days alongside guideline-directed therapy
Front Aging 2026 retrospective review of commercial clinic records (doi 10.3389/fragi.2026.1652582)[3]humanclients of a commercial wellness clinic (retrospective electronic records); compared with NR IV500 mg[3]intravenous, intravenous infusion, average infusion time 97 min; not a subcutaneous dosedaily for 4 consecutive daysintravenous— Human review or observational reportStudy details from the source: Front Aging 2026 retrospective review of commercial clinic records (doi 10.3389/fragi.2026.1652582): NAD+ 500 mg intravenously on four consecutive days, with 30 days follow-up

Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.

Reconstitution calculator

Sizes in the Pepcore catalogue500 mg

Calculator example, not a recommended amount

Concentration
50 mg/mL
Volume to draw
0.005 mL
Units on a U-100 syringe
0.5 units

0102030405060708090100

Properties

CAS
53-84-9
Molecular weight
663.4 g/mol
Formula
Not yet recorded
Sequence
Not yet recorded
Aliases
Nicotinamide adenine dinucleotide, Nadide, beta-NAD
Vial sizes (mg)
100, 250, 500, 750, 1000

Study duration

1 week[2] Human trial

Duration of the cited study. It describes the source and is not a recommended cycle; no off period is stated. Source

Storage notes

Lyophilized
Not yet recorded from a cited source
Reconstituted stability (days)
Not yet recorded from a cited source

Side effects, contraindications and regulatory status

Reported side effects

  • Intravenous NAD+ 500 mg for 4 consecutive days (retrospective clinic records): moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions; symptoms resolved when infusion ended; infusion averaged 97 min (Front Aging 2026).[3] Observational
  • Different substance, same study: intravenous nicotinamide riboside (NR) 500 mg for 4 days gave minor tongue, jaw and arm tingling and mild cramping; infusion averaged 37 min. NR is a precursor, not NAD+ (Front Aging 2026).[3] Observational
  • Systematic review (Ageing Res Rev 2026): no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness; one nonrandomized intravenous NMN study (a different substance) gave short-term safety data.[4] Observational
  • Same review: oral nicotinamide riboside and NMN (precursors, not NAD+, oral route) were generally well tolerated over weeks to months in human studies, per the authors.[4] Observational
  • Randomized trial of intravenous NAD+ 10 mg/day for 7 days vs placebo in 180 adults with ischemic cardiomyopathy heart failure: the abstract reports no adverse-event data (Am J Cardiovasc Drugs 2026).[2] Human trial

Regulatory status

FDA 503A list (updated 2026-05-14): NAD in category 1 (under evaluation), as is NAD disodium reduced (NADH, a different form); beta-NAD disodium salt trihydrate in category 3. Checked 2026-10-20.[1] Source

Report any adverse reaction to a qualified healthcare professional.

What the research says

Summaries of the cited studies, each with its evidence grade.

  • pubmed.ncbi.nlm.nih.gov[2]

    Human trial human

    Single-center randomized placebo-controlled trial in ischemic cardiomyopathy heart failure (Am J Cardiovasc Drugs 2026, doi 10.1007/s40256-025-00764-7; 180 adults): intravenous NAD+ 10 mg/day or placebo for 7 days alongside guideline-directed therapy

    Human clinical trial

  • Front Aging 2026 retrospective review of commercial clinic records (doi 10.3389/fragi.2026.1652582)[3]

    Observational human

    Front Aging 2026 retrospective review of commercial clinic records (doi 10.3389/fragi.2026.1652582): NAD+ 500 mg intravenously on four consecutive days, with 30 days follow-up

    Human review or observational report

Compare vial sizes

Compare vial sizes
SizePriceDoses available from the vial CalculatedCost per dose Calculated
500 mg$69.99——

Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.

Calculated from a default of 2 mL water (adjustable).

PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.

Frequently asked questions

What dose figures are published for NAD+?

Cited figures on this page: 10 mg daily for 7 days, intravenous, trial dose 10 mg per day for 7 days versus placebo [2] (Human clinical trial, evidence grade B); 500 mg daily for 4 consecutive days, intravenous, intravenous infusion, average infusion time 97 min; not a subcutaneous dose [3] (Human review or observational report, evidence grade C). These are summaries of published sources, not medical advice. Each figure links to its source in the references.

What study duration is cited for NAD+?

The cited duration is 1 week, with no off period stated (Human clinical trial). It describes the source, not a recommendation.

What is the regulatory status of NAD+?

FDA 503A list (updated 2026-05-14): NAD in category 1 (under evaluation), as is NAD disodium reduced (NADH, a different form); beta-NAD disodium salt trihydrate in category 3. Checked 2026-10-20.

Compound facts

Recorded molecular weight: 663.4 g/mol.
Recorded CAS number: 53-84-9
Not yet recorded from a cited source.

Sources

https://pubchem.ncbi.nlm.nih.gov/compound/5892
PubMed IDs
33353981

References

Numbered sources used on this page. Markers in the text link here.

  1. fda.gov
  2. pubmed.ncbi.nlm.nih.gov Human trial
  3. Front Aging 2026 retrospective review of commercial clinic records (doi 10.3389/fragi.2026.1652582) pubmed.ncbi.nlm.nih.gov Observational
  4. pubmed.ncbi.nlm.nih.gov Observational

Vial sizes and protocols

  • 500 mgPartner size

Available from Pepcore

Supplied as research material for laboratory use only.

  • NAD+ Research Vial – 500mg 500 mg$69.99
    Shop at PepcoreCoupon code LAUNCH20

PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.